Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients — ScienceDaily
Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children’s Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings…
